Patent DE-102010042506-A1 (DE)
Title: Nuclear medicine examination of a patient comprises e.g. creating a magnetic resonance imaging of an examination region of the patient after administering magnetic resonance contrast agent to patient
Inventor: SCHMIDT SEBASTIAN
IPC: A61B5/055
Filed: 2010-10-15
Abstract: Nuclear medicine examination of a patient comprises: creating a magnetic resonance imaging of an examination region of the patient after administering a magnetic resonance contrast agent (16) to the patient; determining (25) a distribution of the magnetic resonance contrast agent in the examination region from the magnetic resonance imaging; creating a nuclear medicine image of the examination region of the patient, after administering a nuclear medicine tracer (11) to the patient; and correcting (26) the nuclear medicine image. Nuclear medicine examination of a patient comprises: creating a magnetic resonance imaging of an examination region of the patient, after administering a magnetic resonance contrast agent (16) to the patient; automatically determining (25) a distribution of the magnetic resonance contrast agent in the examination region from the magnetic resonance imaging; creating a nuclear medicine image of the examination region of the patient, after administering a nuclear medicine tracer (11) to the patient, where the magnetic resonance contrast agent and the nuclear medicine tracer exhibit equal pharmacokinetic properties; and correcting (26) the nuclear medicine image as a function of the distribution of the magnetic resonance contrast agent into the examination region. Independent claims are also included for: (1) the use of a fluorine-deoxyglucose with a fluorine 19 isotope as the magnetic resonance contrast agent and a fluoro-deoxyglucose with a fluorine-18 isotope as the nuclear medicine tracer during the imaging examination of the patient; (2) the use of a chelate of diethylenetriaminepentaacetic acid with gadolinium as the magnetic resonance contrast agent and a chelate of diethylenetriaminepentaacetic acid with technetium as the nuclear medicine tracer during the imaging examination of the patient; (3) the use of iron oxide nanoparticles, which are radioactively labeled, as the magnetic resonance contrast agent and the nuclear medicine tracer during the imaging examination of the patient, where (a) the magnetic resonance imaging of the examination region of the patient is created after iron oxide nanoparticles are administered to the patient, (b) the distribution of iron oxide nanoparticles in the examination region is determined from the magnetic resonance imaging, (c) the nuclear medicine image of the examination region of the patient is created, and (d) the nuclear medicine image is corrected as a function of the distribution of iron oxide nanoparticles in the examination region, and the steps (a)-(d) are carried out during the examination; (4) the use of a gadolinium chelate as the magnetic resonance contrast agent and the nuclear medicine tracer during the imaging examination of the patient, where (ai) magnetic resonance imaging of the examination region of the patient is created after gadolinium chelate is administered to the patient, (bi) the distribution of gadolinium chelate in the examination region is determined from the magnetic resonance imaging, (ci) the nuclear medicine image of the examination region of the patient is created, and (di) the nuclear medicine image is corrected as a function of the distribution of gadolinium chelate in the examination region, and the steps (ai)-(di) are carried out during the examination; (5) a system comprising a magnetic resonance imaging, a positron emission tomography and a control device; (6) a computer program product, which is directly loaded in a memory of the programmable control device of the positron emission tomography-magnetic resonance system, is fed with program means to carrying out all the steps of the method, when the program is run in the control device; and (7) an electronically readable data carrier with subsequent stored electronically readable control information, which is designed so that the method is carried out by the use of the data carrier in the control device of the positron emission tomography-magnetic resonance system.